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Abstract
Dental implant surgery has developed to a widely used procedure for dental rehabilitation and is a secure and
predictable procedure. Local and systemic risk factors can result in higher failure rates. Diabetes mellitus is a
chronic disease that goes in with hyperglycemia and causes multifarious side effects. Diabetes as a relative
contraindication for implant surgery is controversially discussed. Because the number of patients suffering from
diabetes increases, there are more diabetic patients demanding implant procedures. We aimed to answer the
PICO question “Do diabetic patients with dental implants have a higher complication rate in comparison to
healthy controls?” by a systematic literature search based on the PRISMA statement. We identified 22 clinical
studies and 20 publications of aggregated literature, which were quite heterogeneous concerning methods and
results. We conclude that patients with poorly controlled diabetes suffer from impaired osseointegration, elevated
risk of peri-implantitis, and higher level of implant failure. The influence of duration of the disease is not fully
clear. The supportive administration of antibiotics and chlorhexidine seems to improve implant success. When
diabetes is under well control, implant procedures are safe and predictable with a complication rate similar to
that of healthy patients.




Today, dental implants are one of the restorative methods
to replace missing teeth. Improvements in implant design,
surface characteristics, and surgical protocols made im-
plants a secure and highly predictable procedure with a
mean survival rate of 94.6 % and a mean success rate of
89.7 % after more than 10 years [1]. Implant survival is ini-
tially dependent on successful osseointegration following
placement. Any alteration of this biological process may
adversely affect treatment outcome. Subsequently, as an
implant is restored and placed into function, bone remod-
eling becomes a critical aspect of implant survival in
responding to the functional demands placed on the im-
plant restoration and supporting bone. The critical de-
pendence on bone metabolism for implant survival
leads us to evaluation of certain risk factors. One of the
controversial discussed diseases is diabetes mellitus.
Diabetes mellitus is a chronic metabolic disorder that
leads to hyperglycemia, which raises multiple complica-
tions caused by micro- and macroangiopathy. Diabetic
patients have increased frequency of periodontitis and
tooth loss [2], delayed wound healing [3], and impaired
response to infection. In 1980, more than 150 million
people worldwide were affected and that number had
grown to 350 million by 2008 [4]. This trend highlights
the need for better understanding of diabetes and its
therapy and its impact on dental implant rehabilitation.
In the past, diabetes was long time seen as a relative
risk factor to dental implants. In contrast, today, there
is a change in paradigm. Recent studies offer indirect
evidence for diabetes patients benefiting from oral re-
habilitation based on dental implant therapy. After
tooth loss, patients avoid food which needs more effort
to masticate which can lead to an adverse nutrition with
poor metabolic control. A sufficient dental rehabilitation
allows the patient to improve nutrition and the metabolic
control. On the other hand, it is still unclear how quality
of diabetes therapy and duration of disease influence the
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success of dental implants. The ability to anticipate out-
comes is an essential part of risk management in dental
implant surgery. Recognizing conditions that place the
patient at a higher risk of complications will allow the sur-
geon to make informed decisions and refine the treatment
plan to optimize the outcomes [5].
Therefore, we conducted a systematic review of pub-
lished clinical studies to investigate whether dental im-
plant placement in diabetic vs. non-diabetic patients
yields any detrimental effects on postoperative compli-
cations, peri-implantitis, and implant failure rate. The
main goal is to get a more detailed view on the influ-
ence of quality of glycemic control and duration of dis-
ease to give recommendation for treatment options and
surgical protocols.
Materials and methods
The substructure of the systematic review is based on the
PRISMA statement [6]. The focused question according
to the PICO schema is: “Do diabetic patients with dental
implants have a higher complication rate in comparison
to healthy controls?”
Search strategies
The systematic literature search was performed by an in-
dependent scientist (Burkhard Kunzendorf). The follow-
ing databases were incorporated in the systematic search
for relevant literature: PubMed, Embase, AWMF Online,
National Guideline Clearinghouse, Guidelines Inter-
national Network, and Cochrane Library. The follow-
ing search terms were used: dental implants AND
diabetes, transgingival implants AND diabetes, maxillary
augmentation AND diabetes, mandibular augmentation
AND diabetes, peri-implantitis AND diabetes, Zahnim-
plantate AND Diabetes, Kieferkammaufbau AND Dia-
betes, Periimplantitis AND Diabetes. Electronic search
was complemented by an iterative hand-search in the ref-
erence lists of the already identified articles. The time
period of the literature search was between 10 April and 7
May 2015. Endnote X7 was used for the electronic man-
agement of the literature.
Study inclusion and exclusion criteria
During the first stage of study selection, the titles and
abstracts were screened and evaluated according to the
following inclusion criteria: English or German language,
retrospective and prospective clinical trials, observa-
tional studies, cross-sectional studies, cohort studies,
and case series. During this procedure, the pre-selected
publications were evaluated according to the following
exclusion criteria: in vitro studies, animal studies, case re-
ports with less than 10 patients, and publications older
than 15 years.
Quality and risk of bias assessment of selected studies
A quality assessment of all selected full-text articles was
performed. It made no sense to use the Cochrane collab-
oration tool for assessing risk of bias for randomized con-
trolled studies since the majority of the included studies
were not randomized or retrospective case series. Instead,
a system modified from the US Agency for Healthcare
Research and Quality Methods Guide for Comparative Ef-
fectiveness Reviews was used, which asked for the sources
of possible bias [7]. The criteria were each judged with
low, medium, high, or unknown risk of bias: case selection
bias and confounding, attrition bias (loss of participants),
detection bias (reliable measures), and reporting bias (se-




There are no guidelines existing to the topic of dental
implants and diabetes mellitus. A total of 327 potentially
relevant titles and abstracts were found by the electronic
search and additional evaluation of reference lists. Dur-
ing the first screening, 230 publications were excluded
based on the title and keywords. Additionally, 24 titles
were excluded based on abstract evaluation. Seventy-
three full-text articles were thoroughly evaluated. A total
of 51 papers had to be excluded at this stage because
they did not fulfil the inclusion criteria of the present
systematic review. Twenty-two articles went into qualita-
tive assessment (Fig. 1). Because of too few studies, het-
erogenic study design, and incompletely reported data
like type of diabetes therapy, quality of glycemic control,
and duration of disease, the quantitative data synthesis
could not be performed in the way necessary for meta-
analysis. Additionally, we identified 20 reviews and
meta-analyses. They are excluded from our results.
Evaluation of study quality and risk of bias
The majority (n = 12) of the 22 studies were prospective
and one of these studies was a multicenter study. Eight
were retrospective and two were cross-sectional studies.
Randomization of patients was not readable in any of the
studies (Table 1). Despite a low evidence level in terms of
study design, there were no major concerns about risk of
bias; 13/22 studies were rated with a low risk of bias, 9/22
had a medium risk. No study had a high risk of bias, and
consequently no further study was excluded at this stage
because of bias (Table 2).
Diabetes and osseointegration
Osseointegration describes the process of formation of a
direct interface between the implant and bone, without
intervening soft tissue. This process is prerequisite for im-
plant stability and inflammation-free survival. It includes
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remodeling of the surrounding bone with migrations and
proliferation of osteoblasts and supporting connective tis-
sue. We identified two prospective studies investigating
the influence of type II diabetes on osseointegration. They
are published by the same author but are independent stud-
ies from different years [8, 9]. In both studies, the patients
included were stratified by HbA1c levels as well-controlled
(HbA1c 6.1–8 %), moderately controlled (HbA1c 8.1–
10 %), and poorly controlled (HbA1c ≥10 %). The healthy
control had HbA1c ≤6 %. Patients with poorly controlled
diabetes have lower stability at the first 2 to 6 weeks. In the
following weeks, stability reaches the baseline again, but
reaching baseline takes two times the duration it needs in
the healthy treatment group. Looking at the implant stabil-
ity 1 year after implantation, there is no difference between
the groups, not even to the poorly controlled HbA1c.
Diabetes and peri-implantitis
We found two prospective, two cross-sectional, and one
retrospective study examining the influence of diabetes
on peri-implantitis. The conclusions are quite heteroge-
neous. The study of Aguilar-Salvatierra [10] started to
evaluate 2 years after insertion and found that the num-
ber of patients suffering from peri-implant inflammation
increases with elevated HbA1c values. The population
was divided into well-controlled (HbA1c 6–8 %), moder-
ately controlled (HbA1c 8–10 %), and poorly controlled
(HbA1c >10 %), but there was no healthy control. The
two cross-sectional studies yield an elevated relative risk for
peri-implantitis of 1.9 and 4.1 caused by diabetes [11, 12].
The duration of these studies was 6 months to 5 years and
10 years, respectively. On the other hand, the retrospective
study of Turkyilmaz [13] showed no evidence of diminished
clinical success 1 year after implantation, defined by nega-
tive bleeding on probing, no pathological probing depth,
and a marginal bone loss of 0.3 ± 0.1 mm in a population of
type II diabetics. The results in the prospective study of
Gomez-Moreno [14] show that elevated HbA1c causes
more bone resorption after 3 years, but this effect is
not significant. The bleeding on probing is more often
in the poorly controlled population, but the probing
depth is not increased.
Diabetes and implant survival
Implant survival is an easily defined and measured end-
point for dental implant therapy. Nearly every study re-
ports its implant survival rate. Our literature search
identified 18 publications with these data. We divided
Fig. 1 Selection process of the included literature
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Table 1 List of the included studies and its main characteristics




















Alsaadi 2007 Retrospective Type II Non-
diabetes






Diabetes does not cause higher
failure rate in the first 6 months.
Aguilar-
Salvatierra
2015 Prospective Type II 3 groups
(HbA1c)
n.d. 6–8 (well), 8–10
(moderately),
>10 (poorly)
n.d. 85 85 2 100 vs. 96.6
vs. 86.3
Patients with diabetes can receive
implant-based treatments,
providing they present moderate
HbA1c values. Peri-implantitis
increases with elevated HbA1c.
Anner 2010 Retrospective n.d. Non-
diabetes
n.d. n.d. n.d. 49 diabetes,
475 overall
1626 3 ± 2 97.2 vs. 95 Diabetes was not related to implant
survival in this patient cohort.
Busenlechner 2014 Retrospective n.d. Non-
diabetes
n.d. n.d. n.d. 4316 >10,000 8 years 95.1 vs. 97 Diabetes does not have any
influence on implant survival after






n.d. n.d. n.d. 8 diabetes,
96 overall
225 10 n.d. Significant associations between
implant failure and diabetes (relative
risk 4.8 and 3.3) and peri-implant
diseases and diabetes (relative risk 4.1).













4 months 100 Diabetes has no negative influence;
the quality of glycemic control has
no effect on implant success.
Erdogan 2014 Prospective Type II Non-
diabetes
n.d. Mean 6.8 7.5 12 diabetes,
12 control
43 1 100 No significant difference for wound
healing, radiographic findings,
implant success and volume of
augmentation (guided bone
regeneration with bone scrapes










n.d. 212 (overall) 578 (overall) 6 months–
5 years
n.d. Risk for peri-implantitis in
“uncontrolled” diabetes is 1.9 times
higher compared to the non-
diabetes group.
Fiorellini 2000 Retrospective Types I
and II
None n.d. “Proper levels
of glycemic
control”
8.9 ± 14.3 40 215 6.5 85.6 Survival rate is lower than for general
population, but there is still a
reasonable success rate. Most implant
failures are in the first year after
loading.




10.7 ± 5 16 better, 16
poorly, 19
control
51 1 100 Poor glycemic control negatively
modulated the bone factors during
healing, although diabetes
(regardless of glycemic control) had
no effect on implant stabilization.
Gomez-
Moreno




n.d. 67 67 3 n.d. Elevated HbA1c causes more bone














Table 1 List of the included studies and its main characteristics (Continued)
(moderately)
>10 (poorly)
higher BOP. Probing depth is not
influenced by glycemic control.





n.d. 24 48 4 months 98 Successful implant therapy in patients
suffering poorly controlled diabetes.
No difference between the two
implant systems.
Morris 2005 Prospective Type II Non-
diabetes
n.d. n.d. n.d. 663 255 diabetes,
2632 non-
diabetes
3 92.2 and 93.2,
respectively
Diabetic patients tend to have more
failures than non-diabetic patients.
The use of CHX resulted in a slight
improvement in survival in non-
diabetic patients and in a greater
improvement in type II patients, the
same effect for antibiotic use.
Moy 2005 Retrospective n.d. Non-
diabetes




up to 20 n.d. Significantly increased relative risk for
implant failure (relative risk = 2.75).








n.d. 32 42 4 months Patients with poorly controlled HbA1c
have lower stability in the first 2–6
weeks, but it reaches the baseline in
the following weeks. But reaching the
baseline takes two times the duration
it needs in the non-diabetic
group.
Oates 2014 Prospective Type II Non-
diabetes
n.d. 6–8 (well), >8
(poorly)
n.d. 44 well, 19
poorly, 49
control
220 1 99 The initial implant stability is lower
in diabetic patient, but 1 year after
insertion there in so difference even
in the poorly controlled group.




Type II None Diet, oral,
insulin and
combination
n.d. n.d. 89 178 5 91 vs. 88 Implants in mandibular symphysis in
diabetic patient are a predictable
procedure. Duration of diabetes may
be associated with implant failure,
CHX improves implant survival.
Peled 2003 Retrospective Type II None n.d. “Well-controlled,”
no data for
HbA1c
n.d. 41 141 1 and 5 97.3 vs. 94.4 No correlation was found between
failed implants and glucose level.
The clinical outcome of dental
implants in a selected group of
patients with well-controlled type II
diabetes mellitus is satisfying and
encouraging.
Tawil 2008 Prospective Type II Non-
diabetes








1 to 12 97.2 vs. 98.8 No significant difference for implant
survival between the groups and no
difference between good and
medium glycemic control for bone
resorption. Augmentations caused
no complications. Duration of














Table 1 List of the included studies and its main characteristics (Continued)
Tatarakis 2013 Prospective Type II None n.d. Mean 7.1 n.d. 32 >32 1 n.d. The clinical, microbiological, salivary
biomarkers and psychosocial profiles
of patient with diabetes under good
control are very similar to those of
non-diabetes.
Turkyilmaz 2010 Retrospective Type II None Diet, oral,
insulin and
combination
5–10 5–21 10 23 1 100 No evidence of diminished clinical
success, BOP negative, no pathological
probing depth, marginal bone loss
0.3 ± 0.2 mm.
Zupnik 2011 Retrospective n.d. Non-
diabetes
n.d. n.d. n.d. n.d. 25 diabetes,
316 non-
diabetes
4 96.4 (global) Implant failure (explantation) is 2.57
times higher for patient with diabetes
than patients without diabetes after
4 years.














them into two groups: the first one covers 7 studies with
observation time up to 1 year (6 prospective, 1 retro-
spective studies), the second one longer periods (4 pro-
spective, 1 cross-sectional, and 6 retrospective studies).
In the short-time group, 5 of the studies had a healthy
control group. The result for implant survival in dia-
betics is 100 to 96.4 %, which does not differ from the
healthy control [9, 15–18]. The 2 studies without control
group report a 100 % survival rate 4 months and 1 year
after implantation [13, 19]. The time periods in the
long-time group differ from 1 year up to 20 years and
are very heterogeneous. We found 4 prospective, 6
retrospective, and 1 cross-sectional study. Seven studies
compared the diabetic survival rates to healthy popula-
tion, and results are equivocal. On the one hand, sur-
vival rates of diabetics are similar to healthy control:
95.1 vs. 97 %, 97.2 vs. 95 %, 92 vs. 93.2 %, and 97 vs.
98.8 % [20–23]. On the other hand, there are 2 studies
reporting relative risk for implant failure in diabetic pa-
tients elevated to 4.8 and 2.75, respectively [11, 24]. The
studies without a healthy control present survival rates
from 100 to 86 % [10], 97.3 and 94.4 % after 1 and
5 years [25], and 91 to 88 % after 5 years [26], which are
comparable to survival rates in healthy individuals.
There is one work that demonstrates survival rate of
85.6 % after 6 years, which is lower than that in healthy
population. The most implant failures were observed in
the first year after prosthetic loading [27].
Diabetes and bone augmentation
We identified two prospective studies that evaluated “ad-
vanced” implant surgery covering sinus lift procedure and
guided bone regeneration. The study of Erdogan consists
of type II diabetics moderately and well-controlled (HbA1c
6–7.5 %) with a mean duration of disease of 7.5 years and
a healthy control group. Augmentation of the maxilla was
performed by guided bone regeneration with autologous
bone from the mandibular ramus harvested by bone
scrapers, a synthetic bone substitute, and collagen mem-
brane. The result after 1 year is that patients with HbA1c
Table 2 Risk of bias of the included studies
















Alsaadi 2007 Retrospective H U U L L L
Aguilar-
Salvatierra
2015 Prospective H L L L L L
Anner 2010 Retrospective H U U L L M
Busenlechner 2014 Retrospective H L U L L L
Daubert 2015 Cross-sectional H L U L L L
Dowell 2007 Prospective H L L L M M
Erdogan 2014 Prospective H L L L M M
Ferreira 2006 Cross-sectional H L L L L L
Fiorellini 2000 Retrospective H M U M L M
Ghiraldini 2015 Prospective H L L L L L
Gomez-
Moreno
2014 Prospective H L L L L L
Khandelwal 2011 Prospective L L L M L L
Morris 2005 Prospective H L L M L M
Moy 2005 Retrospective H L U M L M
Oates 2009 Prospective H L L L L L
Oates 2014 Prospective H L M L L L
Olson 2000 Prospective,
multicenter
H L U L L L
Peled 2003 Retrospective H L U M L M
Tawil 2008 Prospective H L L M L M
Tatarakis 2013 Prospective H L L L L L
Turkyilmaz 2010 Retrospective H L U L L L
Zupnik 2011 Retrospective H L U M L M
L low, M medium, H high, U unknown risk of bias
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levels <7.5 % may undergo staged guided bone regener-
ation securely [16]. The other study consisted of a larger
group of type II diabetic patients and healthy control
which were treated with simple or advanced implant
therapy. The authors conclude that well- to fairly well-
controlled diabetic patients with a mean HbA1c of 7.2 %
had the same overall survival rate as controls in conven-
tional and advanced implant therapy. No difference was
seen when looking at bone resorption [23].
Influence of quality of glycemic control
When looking at the question, if diabetes is a risk factor
for dental implants, it is not sufficient to decide having dia-
betes or not. The greater the impact of diabetes, the worse
the patient handles with glycemic control. In international
studies, the percentage of glycosylated hemoglobin is an
indicator for glycemic levels from previous 6–8 weeks. Un-
fortunately, many studies do not provide data of HbA1c.
Some authors call their patient “under well control” or
“poorly controlled,” without representing any definition.
Our search identified seven studies with a clear definition
of different qualities of glycemic control by HbA1c. Three
defined HbA1c 6–8 % as good, 8–10 % as moderately, and
>10 % as poorly controlled. Two studies called HbA1c
<8 % better and >8 % poorly controlled and another <7 %
well, 7–9 % moderately, and >9 % poorly controlled. While
four studies conclude better implant survival and less
peri-implant complications in the well-controlled group
[8, 10, 14, 17], the three others see no difference in
implant success even in the poorly controlled patients
[9, 15, 23]. The study of Khandelwal treated exclusively
patients with poor glycemic control (HbA1c 7.5–11.4 %)
and had 98 % implant survival, after 4 months; therefore,
he concluded that implant therapy is successful even in
poorly controlled diabetes [19].
Influence of duration of diabetes disease
It is plausible that with extended duration of diabetes,
the systemic side effects increase. However, the influence
of duration of the disease on implant surgery outcome is
only very little examined. Most of the included studies
(17 of 22) provided no data about duration since diagno-
sis of diabetes. In five studies, these data were given, but
only two of them analyzed the influence on the implant
survival. While Olsen concludes that the duration of dia-
betes may be associated with implant failure [26], Tawil
says that implant survival is independent from diabetes
duration [23].
Influence of supportive therapy
Although there is some controversy over the use of anti-
biotics in healthy patients, these are recommended in
diabetic patients in implant surgery. The reason is the
impaired immune system, which can lead to wound
infections and healing complications. Some authors indi-
cate the administration of antibiotics for 5–7 days post-
operatively; others support the view that there is no
significant reduction of wound infection when using an-
tibiotics more than 1 day after surgery. Our literature
search resulted in one prospective study that shows a
clear benefit using preoperative antibiotics in both type
II diabetics and non-diabetics. For implants in the non-
type II diabetic group, survival for those implants placed
with preoperative antibiotics was 4.5 % higher than im-
plants not provided coverage at placement surgery. This
improvement in survival was even greater (10.5 %) for
those in the type II diabetic group. These outcomes are
clinically important and should be considered clinically
significant [22]. But the authors do not describe which
antibiotic they used and how long it was administered.
There was a large improvement in implant survival
in the type II diabetic patients when chlorhexidine
(CHX) (95.6 %, 4.4 % failures) was used at the time of
implant placement, as compared to when CHX was not
used (86.5 %, 13.5 % failures). This difference in sur-
vival (9.1 %) was large enough to be considered clinic-
ally significant but was not found in the non-type II
diabetic patient. For the non-diabetic group, survival
increased only slightly when CHX was used (94.3 %,
5.7 % failures), compared to when CHX was not used
(91.8 %, 8.2 % failures) [22, 26].
Conclusions
The literature included to this review is very heteroge-
neous concerning the investigated objects, methods, and
conclusions. Diabetes is a group of metabolic diseases in
which there are high blood sugar levels over a prolonged
period. When looking at the complications and side ef-
fects resulting from diabetes, it is important to know
which type of diabetes the patient suffers from, if there
is any therapy, which kind of therapy, the grade of gly-
cemic control, and duration of the disease. The previ-
ously described micro- and macroangiopathies develop
with the duration and repetitions of elevated glycemic
periods. In most studies, these information are missing
and there is only a dichotomy classification of diabetes
or healthy. Most studies include patients with well-
controlled diabetes, and there is no or little effect on
implant survival. Many authors conclude that prospect-
ive long-time studies are needed to answer the issues.
On the other hand, it would be non-ethical to observe
patients with poor glycemic control, because health-
threatening systemic side effects developed.
Analyzing the available studies, we conclude as follows:
Dental implants are safe and predictable procedures
for dental rehabilitation in diabetics. The survival rate of
implants in diabetics does not differ from the survival
rate in healthy patients within the first 6 years, but in
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the long-term observation up to 20 years, a reduced im-
plant survival can be found in diabetic patients. Patients
with poorly controlled diabetes seem to have delayed
osseointegration following implantation. After 1 year,
there is no difference between diabetic and healthy indi-
viduals, not even to the poorly controlled HbA1c. There-
fore, we recommend avoiding immediate loading of the
implants. In the first years after implant insertion, there
seems to be no elevated risk of peri-implantitis; but in
the long-term observation, peri-implant inflammation
seems to be increased in diabetic patients. Therefore, a
risk-adapted dental recall is helpful to detect early signs
of gingivitis, which can easily be treated by dental/im-
plant cleanings to avoid serious peri-implant infection.
We found some hints that good glycemic control im-
proves osseointegration and implant survival. Therefore,
and to avoid other long-term side effects, the practitioner
should ask for the HbA1c and if necessary improvement
of antidiabetic therapy should be aimed. In the literature,
we found no evidence that bone augmentation procedures
like guided bone regeneration and sinus lifts have a higher
complication and failure rate in patients with well- to fairly
well-controlled diabetes. To improve implant survival and
reduce postoperative complications, supportive therapy
consisting of prophylactic antibiotics and chlorhexidine
mouth rinse is recommended.
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